Prime Medicine
PRME
121 hedge funds and large institutions have $145M invested in Prime Medicine in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 33 closing their positions.
20% more capital invested
Capital invested by funds: $120M → $145M (+$24.6M)
17% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $1.22M
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.34% less ownership
Funds ownership: 46.04% → 44.7% (-1.3%)
3% less funds holding
Funds holding: 125 → 121 (-4)
12% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$3.61M |
| 2 |
CC
Casdin Capital
New York
|
+$1.85M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.26M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$804K |
| 5 |
FAM
Fred Alger Management
New York
|
+$591K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.52M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.32M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$2.06M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$2.05M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$2.05M |
PRME Hedge Fund Activity: Q2 2025 in Review
121 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q2 2025, worth a combined $145M — up 20% from $120M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of PRME and 29 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 36 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $3.61M. The largest seller was Millennium Management, cutting an estimated $2.52M.
- 121 institutional investors held Prime Medicine (PRME) as of Q2 2025, down from 125 in Q1 2025.
- Funds reported $145M of Prime Medicine stock for Q2 2025, up 20% quarter-over-quarter.
- 29 funds opened new Prime Medicine positions in Q2 2025 and 33 closed out, a net change of -4 holders.
- The largest Prime Medicine buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $3.61M added.
- The largest Prime Medicine seller in Q2 2025 was Millennium Management, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2025.